AIS Healthcare’s Advanced Infusion Care Announces Joint Study with Grifols to Continue Improving Patient Care

Study to observe effects of subcutaneous immunoglobulin therapy on individuals living with primary immune deficiencies

DALLAS--(BUSINESS WIRE)-- Advanced Infusion Care (AIC), a division of AIS Healthcare, today announced an agreement to conduct a joint study with Grifols, a leading global provider of essential plasma-derived and transfusion medicines, to observe the effects of subcutaneous immunoglobulin (SCIG) products on individuals living with primary immune deficiencies (PID). AIC and Grifols’ Satisfaction and Outcomes in Primary Immune Deficiency patients (SOPID) study will observe 60 patients across a three-month period who are beginning SCIG therapy. The purpose of the study is to determine if there are differences in patient experience and satisfaction with immunoglobulin treatments, which will help physicians, pharmacists, and nurses ensure patients living with immunodeficiencies receive the therapy that best fits their medical and lifestyle needs.

“Grifols has an impressive track record of producing innovative, high-quality medicines for patients living with chronic and rare diseases. We are proud to partner with their team to carry out a study that will continue advancing our quality of care to better serve individuals living with primary immune deficiencies through SCIG treatment,” said Jud Hall, President of AIC. “Grifols and AIC are committed to helping patients fight infections, stay healthy, and receive the highest quality care.”

According to the National Institute of Allergy and Infectious Diseases, there are over 200 different forms of PID affecting approximately 500,000 individuals in the United States. SCIG treatment is effective in preventing infections for this patient population and has a low incidence of serious adverse effects. Other advantages of SCIG treatment include ease of administration, elimination of the need for vascular access, ability to infuse at home, and a steady state of immunoglobulin levels.

The joint study between AIC and Grifols seeks to determine if there are differences in patient tolerability and satisfaction with immunoglobulin treatments, ensuring the best quality of care for patients living with immunodeficiencies. The results will provide physicians and patients with more information as they make decisions and plan long-term treatment strategies.

AIC’s network of 180 nurses operates in 40 states, consistently delivering patient-specific, specialized in-home infusion services, including SCIG treatment. The provider recently announced the opening of a new pharmacy location in Maryland in addition to the expansion of its nurse specialist offerings in Connecticut, Massachusetts, and Rhode Island. AIC’s comprehensive suite of medications and team-based approach to SCIG therapy is now available to patients with complex medical conditions like PID across the Mid-Atlantic and Northeast.

In May 2023, the National Home Infusion Association’s (NHIA) Infusion Journal featured an AIC case study detailing the importance of assessing each patient’s unique circumstances in order to guide decisions for immunoglobulin treatment. In partnership with Grifols, the SOPID study will build on this work to assist physicians in better understanding how different SCIG products can maximize patient quality of life.

Physicians interested in AIC care services should contact their AIC representatives to get started or visit us at www.aiscaregroup.com/our-divisions/infusion-care/.

About AIS Healthcare

Advancing quality. Improving lives.

As the leading provider of targeted drug delivery and infusion care solutions, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected in everything we do.

Learn more at aiscaregroup.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231023413274/en/